35. Management of Graves Disease: A Review.
Graves disease is the most common cause of persistent hyperthyroidism in adults. Approximately 3% of women and 0.5% of men will develop Graves disease during their lifetime.
36. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
作者: Roger Stupp.;Sophie Taillibert.;Andrew A Kanner.;Santosh Kesari.;David M Steinberg.;Steven A Toms.;Lynne P Taylor.;Frank Lieberman.;Antonio Silvani.;Karen L Fink.;Gene H Barnett.;Jay-Jiguang Zhu.;John W Henson.;Herbert H Engelhard.;Thomas C Chen.;David D Tran.;Jan Sroubek.;Nam D Tran.;Andreas F Hottinger.;Joseph Landolfi.;Rajiv Desai.;Manuela Caroli.;Yvonne Kew.;Jerome Honnorat.;Ahmed Idbaih.;Eilon D Kirson.;Uri Weinberg.;Yoram Palti.;Monika E Hegi.;Zvi Ram.
来源: JAMA. 2015年314卷23期2535-43页
Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly.
37. Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial.
作者: Christopher J Hawkey.;Matthieu Allez.;Miranda M Clark.;Myriam Labopin.;James O Lindsay.;Elena Ricart.;Gerhard Rogler.;Montserrat Rovira.;Jack Satsangi.;Silvio Danese.;Nigel Russell.;John Gribben.;Peter Johnson.;Jerome Larghero.;Catherine Thieblemont.;Sandro Ardizzone.;Daan Dierickx.;Adalberto Ibatici.;Timothy Littlewood.;Francesco Onida.;Urs Schanz.;Severine Vermeire.;Jean-Frederic Colombel.;Jean-Paul Jouet.;Elizabeth Clark.;Riccardo Saccardi.;Alan Tyndall.;Simon Travis.;Dominique Farge.
来源: JAMA. 2015年314卷23期2524-34页
Case reports and series suggest hematopoietic stem cell transplantation (HSCT) may benefit some patients with Crohn disease.
|